Detailed price information for Nervgen Pharma Corp (NGENF) from The Globe and Mail including charting and trades.

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin ...

After hours: January 3 at 6:59:34 PM EST Loading Chart for CATX ...

Psilocybin is under clinical development by Silo Pharma and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...

Geode Capital Management LLC grew its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) by 12.5% during the third quarter, Holdings Channel reports. The institutional ...

Clarity announced in August that its phase 1/2a trial in paediatric patients with ... of tumour targets than small molecules or small peptides. Importantly, the three-dimensional shape of the ...

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...

Phase 2a topline data for POLB 001 in the second half of 2026 and (iii) primary completion of the Phase 1b trial of HB-500 in ...